Skip to Main Content

Author Details

Mengdie Wang
University of Massachusetts Chan School of Medicine
2016
15
7
PMIDPaper TitleJournal TitlePublished Year
37134151Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer.Sci Transl Med2023
37221223ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor progression.Oncogene2023
37134152Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.Sci Transl Med2023
35344032PD-LI promotes rear retraction during persistent cell migration by altering integrin β4 dynamics.J Cell Biol2022
31477840Centrosome loss results in an unstable genome and malignant prostate tumors.Oncogene2020
32454466Data-driven respiratory gating based on localized diaphragm sensing in TOF PET.Phys Med Biol2020
30699045A method of quantifying centrosomes at the single-cell level in human normal and cancer tissue.Mol Biol Cell2019
33654897Immunofluorescence-based Determination of Centrosome Number in Tissue Samples.Bio Protoc2019
31262785Real-time imaging of integrin β4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing.J Cell Sci2019
31235595The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.Proc Natl Acad Sci U S A2019
31337652Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.Cancer Res2019
30865564Integrin α6β4E variant is associated with actin and CD9 structures and modifies the biophysical properties of cell-cell and cell-extracellular matrix interactions.Mol Biol Cell2019
27609833A basal cell defect promotes budding of prostatic intraepithelial neoplasia.J Cell Sci2017
26843244A novel approach to assess the treatment response using Gaussian random field in PET.Med Phys2016
27009859TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Oncotarget2016
  • 1 - 15 of 15

Recommended Authors

Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 1
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 0
Paris Sciences Lettres University PSL, Institut CURIE
Career Start Year 2012
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 0
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 1
Center for Cancer Research, National Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
College of Optical Science and Engineering, Zhejiang University
Career Start Year 2004
Number of shared co-authors 1
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2004
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 0
University of British Columbia
Career Start Year 2002
Number of shared co-authors 2
University of Toronto
Career Start Year 2002
Number of shared co-authors 0
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 0
19University of Wisconsin Carbone Cancer Center.
Career Start Year 2000
Number of shared co-authors 2
University of British Columbia
Career Start Year 2000
Number of shared co-authors 1
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 1
Foundation for the Finnish Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Cedars-Sinai Medical Center
Career Start Year 1997
Number of shared co-authors 2
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 1
Georgetown University
Career Start Year 1993
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1992
Number of shared co-authors 1
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 1
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 0
Queen's University
Career Start Year 1982
Number of shared co-authors 1
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 2
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 1

Collaborators

University of Arizona Cancer Center, College of Medicine, University of Arizona
Co-authored papers 6
University of Utah
Co-authored papers 4
Massachusetts General Hospital
Co-authored papers 2
Beijing Tongren Hospital, Capital Medical University
Co-authored papers 2
Co-authored papers 2
Massachusetts General Hospital, the Gordon Center for Medical Imaging
Co-authored papers 1
Co-authored papers 1
Weill Medical College of Cornell University
Co-authored papers 1
Co-authored papers 1
Massachusetts General Hospital
Co-authored papers 1
Co-authored papers 1
Tsinghua University
Co-authored papers 1
Tsinghua University
Co-authored papers 1
Siemens Medical Solutions USA, Inc.
Co-authored papers 1